Skip to Content

Sanofi SA SNYNF

Morningstar Rating
$97.70 +0.94 (0.97%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SNYNF is trading at a 362% premium.
Price
$96.23
Fair Value
$186.42
Uncertainty
High
1-Star Price
$872.23
5-Star Price
$87.29
Economic Moat
Yxmwgpm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNYNF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$96.76
Day Range
$97.7097.70
52-Week Range
$86.12110.16
Bid/Ask
$95.73 / $100.95
Market Cap
$122.10 Bil
Volume/Avg
200 / 32,748

Key Statistics

Price/Earnings (Normalized)
10.63
Price/Sales
2.40
Dividend Yield (Trailing)
4.20%
Dividend Yield (Forward)
4.54%
Total Yield
4.56%

Company Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
87,994

Competitors

Valuation

Metric
SNYNF
MRK
NVS
Price/Earnings (Normalized)
10.6360.3614.90
Price/Book Value
1.598.225.29
Price/Sales
2.405.434.28
Price/Cash Flow
11.8419.1014.19
Price/Earnings
SNYNF
MRK
NVS

Financial Strength

Metric
SNYNF
MRK
NVS
Quick Ratio
0.830.680.61
Current Ratio
1.271.250.90
Interest Coverage
8.403.9711.32
Quick Ratio
SNYNF
MRK
NVS

Profitability

Metric
SNYNF
MRK
NVS
Return on Assets (Normalized)
5.22%13.39%
Return on Equity (Normalized)
13.56%31.09%
Return on Invested Capital (Normalized)
8.29%19.67%
Return on Assets
SNYNF
MRK
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoNmwcfdpwVlbg$744.3 Bil
JNJ
Johnson & JohnsonXfdcrxxDyqm$372.2 Bil
MRK
Merck & Co IncBrzvjbwqDljv$331.8 Bil
ABBV
AbbVie IncWntdntcdqFkvt$290.2 Bil
AZN
AstraZeneca PLC ADRQnfcwkytmWkj$238.2 Bil
RHHBY
Roche Holding AG ADRSsbtgzcwvsGhjf$211.1 Bil
NVS
Novartis AG ADRQtsrbjrtPhclw$209.6 Bil
AMGN
Amgen IncWttvwvrrcmDkkx$167.6 Bil
PFE
Pfizer IncLdfgcdgDprr$161.7 Bil
SNY
Sanofi SA ADRVdplqhrwmTdpw$121.2 Bil

Sponsor Center